Brief: Ono Announces Encouraging Efficacy Signals Of ONO-2808, A S1P5 Receptor Agonist, In An Interim Analysis Of Ongoing Phase 2 Clinical Trial In Patients With Multiple System Atrophy
09/10/2025 13:20
Oct 9 (Reuters) - Ono Pharmaceutical Co Ltd 4528.T: ONO ANNOUNCES ENCOURAGING EFFICACY SIGNALS OF ONO-2808, A S1P5 RECEPTOR AGONIST, IN AN INTERIM ANALYSIS OF ONGOING PHASE 2 CLINICAL TRIAL IN PATIENTS WITH MULTIPLE SYSTEM ATROPHY ONO PHARMACEUTICAL: MSA TENDED TO BE SLOWER IN ONO-2808 GROUP IN TERMS OF CLINICAL OUTCOME ENDPOINT ONO PHARMACEUTICAL CO LTD: ALL DOSES WERE WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE Source text: ID:nBw8n3gTNa Further company coverage: 4528.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours